91012-55-4Relevant academic research and scientific papers
Novel 2-methoxyacylhydrazones as potent, selective PDE10A inhibitors with activity in animal models of schizophrenia
Cutshall, Neil S.,Onrust, Rene,Rohde, Alex,Gragerov, Sasha,Hamilton, Lauren,Harbol, Kevin,Shen, Hui-Rong,McKee, Shawn,Zuta, Charles,Gragerova, Galina,Florio, Vince,Wheeler, Thomas N.,Gage, Jennifer L.
scheme or table, p. 5595 - 5599 (2012/09/21)
A series of 2-methoxyacylhydrazones were optimized to yield compounds with high affinity for PDE10A. Several compounds demonstrated efficacy in animal models of schizophrenia, including conditioned avoidance response and a pro-psychotic phencyclidine hyperactivity model.
PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS
-
Page/Page column 21, (2011/10/04)
Compounds that inhibit PDE10 are disclosed that have utility in the treatment of a variety of conditions, including (but not limited to) psychotic, anxiety, movement disorders and/or neurological disorders such as Parkinson's disease, Huntington's disease, Alzheimer's disease, encephalitis, phobias, epilepsy, aphasia, Bell's palsy, cerebral palsy, sleep disorders, pain, Tourette's syndrome, schizophrenia, delusional disorders, drug-induced psychosis and panic and obsessive-compulsive disorders. Pharmaceutically acceptable salts, stereoisomers, solvates and prodrugs of the compounds are also provided. Also disclosed are compositions containing a compound in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for inhibiting PDE10 in a warm-blooded animal in need of the same.
